LFCR FY2025 SEC EDGAR DEF 14A #138 of 168 in industry

Lifecore Biomedical, Inc. \de\ CEO pay ratio

The CEO earned $6.5M in FY2025 against median worker pay of $545,635 · Chemicals & Pharmaceuticals.

Chemicals & Pharmaceuticals peers All rankings
State
DE
Filing date
2026-04-24
Industry
Chemicals & Pharmaceuticals
Industry rank
#138/168

Data updated August 2026

Subscribe to Lifecore Biomedical, Inc. \de\ CEO pay filing updates (RSS)

CEO-to-worker pay ratio
12:1
Below Average (Scale: 0–1000:1)
CEO pay
$6.5M
Median worker
$545,635

Answer first

Lifecore Biomedical, Inc. \de\'s FY2025 CEO total of $6.5M ranks #800 of 1,423 complete filings; its 12:1 pay ratio ranks #1262. Dollar rank is not ratio rank.

According to the same FY2025 complete-filing cohort used on the rankings boards (CEO total, median worker, and ratio all present). Median worker pay is $545,635. Industry placement uses the FY2025 SIC-28 peer cohort (# 138 of 168, 18th percentile - among the lower quartile of industry peers by pay ratio). Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.

Dollar rank
#800
$6.5M of 1,423 FY2025
Ratio rank
#1262
12:1 of 1,423
Industry pct
18th
among the lower quartile of industry peers by pay ratio

How Lifecore Biomedical, Inc. \de\ ranks nationally

Lifecore Biomedical, Inc. \de\ CEO pay vs. every FY2025 complete filing

Total CEO compensation, the full national distribution, this company marked

$6,547,620 44th percentile higher than 44% of 1,423 companies

$0–$2,500,000: 304 companies (21%). Below this entry. $2,500,000–$5,000,000: 182 companies (13%). Below this entry. $5,000,000–$7,500,000: 208 companies (15%). This entry sits in this band. $7,500,000–$10,000,000: 192 companies (13%). Above this entry. $10,000,000–$12,500,000: 139 companies (10%). Above this entry. $12,500,000–$15,000,000: 91 companies (6%). Above this entry. $15,000,000–$17,500,000: 88 companies (6%). Above this entry. $17,500,000–$20,000,000: 54 companies (4%). Above this entry. $20,000,000–$22,500,000: 24 companies (2%). Above this entry. $22,500,000–$25,000,000: 34 companies (2%). Above this entry. $25,000,000–$27,500,000: 24 companies (2%). Above this entry. $27,500,000–$30,000,000: 16 companies (1%). Above this entry. $30,000,000–$32,500,000: 10 companies (1%). Above this entry. $32,500,000–$35,000,000: 7 companies (0%). Above this entry. $35,000,000–$37,500,000: 9 companies (1%). Above this entry. $37,500,000–$40,000,000: 6 companies (0%). Above this entry. $40,000,000–$42,500,000: 1 companies (0%). Above this entry. $42,500,000–$45,000,000: 1 companies (0%). Above this entry. $45,000,000–$47,500,000: 6 companies (0%). Above this entry. $47,500,000–$50,000,000: 27 companies (2%). Above this entry. This company $0 $50M+ every complete-filing company, bucketed by value

Each bar is a $2500K-wide band; taller bars hold more companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source SEC DEF 14A Section 953(b) disclosures, PlainCEOPay extract · FY2025

Lifecore Biomedical, Inc. \de\ vs. Chemicals & Pharmaceuticals peers

CEO total pay ($6.5M) against pay ratio (12:1) for Lifecore Biomedical, Inc. \de\ (marked) and its 5 closest same-industry peers, against the Chemicals & Pharmaceuticals industry median on both axes.

Pay + gap both highContained pay, wide gapHigh pay, contained gapBelow peer norms on both02072365.44144730.96217096.38289461.87.3:116.4:125.5:134.6:143.6:1CEO total payPay ratio (CEO : median worker)Lifecore Biomedical, Inc. \de\, CEO total pay: 6547620 · Pay ratio (CEO : median worker): 12:1Lifecore Biomedical, Inc. \de\Lexicon Pharmaceuticals, Inc., CEO total pay: 3553953 · Pay ratio (CEO : median worker): 13:1Lexicon Pharmaceuticals, Inc.Puma Biotechnology, Inc., CEO total pay: 3062337 · Pay ratio (CEO : median worker): 11:1Puma Biotechnology, Inc.Cumberland Pharmaceuticals Inc, CEO total pay: 101000 · Pay ratio (CEO : median worker): 10:1Cumberland Pharmaceuticals IncAcadia Pharmaceuticals Inc, CEO total pay: 2574405 · Pay ratio (CEO : median worker): 9:1Acadia Pharmaceuticals IncAmylyx Pharmaceuticals, Inc., CEO total pay: 2685240 · Pay ratio (CEO : median worker): 9:1Amylyx Pharmaceuticals, Inc.
Lifecore Biomedical, Inc. \de\ vs. Chemicals & Pharmaceuticals peers, plotted against the industry's $7.9M median CEO total and 42:1 median pay ratio.

Ratio bands among Chemicals & Pharmaceuticals peers

Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.

CEO Compensation Breakdown, FY2025

A component-level pay breakdown is not reported in Lifecore Biomedical, Inc. \de\'s structured SEC pay-ratio disclosure. See our methodology →

Industry Comparison - Chemicals & Pharmaceuticals

This Company's Ratio
12:1
Industry Median Ratio
42:1
Industry Median CEO Pay
$7.9M
This CEO's Pay
$6.5M
Companies in Industry
168
vs. Industry Median
Below
#138 of 168 by pay ratio in this industry View all companies in Chemicals & Pharmaceuticals →

Lifecore Biomedical, Inc. \de\: near-parity Item 402(u) ratio

Lifecore Biomedical, Inc. \de\'s FY2025 ratio 12:1 ranks #138 of 168 Chemicals & Pharmaceuticals filers (18th percentile). the CEO earned 12× the median employee ($545,635) in FY2025.

At $545,635 median worker pay, the FLOOR stamp is near pay-parity territory under HEAVY CEO total.

CEO Total Pay

$6.5M

FY2025 Summary Compensation, below median

Pay Ratio

12:1

Below typical

Lifecore Biomedical, Inc. \de\ in the lower Chemicals & Pharmaceuticals third

Lifecore Biomedical, Inc. \de\'s FY2025 ratio 12:1 ranks #138 of 168 Chemicals & Pharmaceuticals filers (18th percentile). The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; Lifecore Biomedical, Inc. \de\'s $6.5M CEO total is at or below the $7.9M industry median CEO pay.

Dollar rank #800 and ratio rank #1262 split - treat 12:1 as a disclosure, not a fairness score. Open Chemicals & Pharmaceuticals peers.

Key Data, FY2025

Total Compensation
$6.5M
Median Employee Pay
$545,635
Pay Ratio
12:1
Filing Date
2026-04-24

Company Info

Ticker
LFCR
CIK
1005286
Industry
Chemicals & Pharmaceuticals
SIC Code
2834
State
DE
View SEC filings →
SEC EDGAR DEF 14A for CIK 1005286, FY2025. Informational only, not investment advice. Verify on EDGAR.

Read our methodology - how this data is sourced, computed, and verified. Lifecore Biomedical, Inc. \de\'s FY2025 ratio 12:1 ranks #138 of 168 Chemicals & Pharmaceuticals filers (18th percentile).

Read with Lifecore Biomedical, Inc. \de\

ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps FLOOR · HEAVY · ELITE-MED.

James Hardie Industries plc · HEAVY

ABS(ceo_total_comp) peer at $6.5M (Δ $2K lighter vs Lifecore Biomedical, Inc. \de\); MODEST · ELITE-MED vs this page's FLOOR · HEAVY · ELITE-MED.
ProPetro Holding Corp. · HEAVY

ABS(ceo_total_comp) peer at $6.6M (Δ $15K heavier vs Lifecore Biomedical, Inc. \de\); MODEST · ELITE-MED vs this page's FLOOR · HEAVY · ELITE-MED.
Monro, Inc. · HEAVY

ABS(ceo_total_comp) peer at $6.5M (Δ $20K lighter vs Lifecore Biomedical, Inc. \de\); MID · PAR-MED vs this page's FLOOR · HEAVY · ELITE-MED.
Pool Corp · HEAVY

ABS(ceo_total_comp) peer at $6.5M (Δ $24K lighter vs Lifecore Biomedical, Inc. \de\); MID · PAR-MED vs this page's FLOOR · HEAVY · ELITE-MED.
Lexicon Pharmaceuticals, Inc. (SIC 28 pole)

Lexicon Pharmaceuticals, Inc. stamps FLOOR · MID$ nearest in-SIC by ABS(pay_ratio) to Lifecore Biomedical, Inc. \de\'s FLOOR filing.
National dual ranks · #800/#1262

Lifecore Biomedical, Inc. \de\'s FY2025 package sits #800 by CEO dollars and #1262 by ratio under HEAVY · FLOOR.
Ratio primer · FLOOR

Lifecore Biomedical, Inc. \de\'s FLOOR stamp sits in the lower Item 402(u) band - start with how the ratio is disclosed before comparing peers.
Data sourced from SEC EDGAR DEF 14A for Lifecore Biomedical, Inc. \de\ (CIK 1005286), FY2025. See our methodology. Aggregated by PlainCEOPay as of August 2026.

Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.